I. MODIFIED AGREEMENTS

Biotech Co.* (Symbol)

Pharma Co. (Country)

Change from original agreement

Disclosed Funding (M)

Terms/Details (Date)

3-Dimensional Pharmaceuticals Inc. (DDDP)

Boehringer Ingelheim Pharmaceuticals Inc. (Germany)

Extension to the December 1999 drug discovery collaboration through March 31, 2003

ND

Agreement is to discover drugs for asthma and allergic disease; 3DP will receive an additional up-front payment, research and development funding, and is eligible for milestone payments and royalties (4/25)

ArQule Inc. (ARQL)

Sankyo Co. Ltd. (Japan)

Extended agreement from 1997 to provide Sankyo access to ArQule's Compass Array libraries through 2004

ND

ArQule may receive delivery fees, research payments, milestone payments and royalties from sales of any resulting products (4/3)

Genome Therapeutics Corp. (GENE)

Aventis Pharma AG (Germany)

Extended licensing agreement renewing Aventis' access to Genome Therapeutic's PathoGenome database

ND

Aventis will continue to have non-exclusive access to the database in exchange for an annual subscription fee and royalties on any small molecules developed (4/3)

Icagen Inc.*

Abbott Laboratories Inc.

Extension to the discovery and development collaboration to include the development of small-molecule drugs that target ion channels to treat urological disorders such as incontinence, benign prostatic hypertrophy and sexual dysfunction

$12

The companies entered the $12M deal in December 1997; the collaboration was extended for two years (3/7)

Isis Pharmaceuticals Inc. (ISIP)

Merck & Co. Inc.

Extended research collaboration to discover drug candidates to treat patients infected with the hepatitis C virus

ND

Agreement is extended for one year, giving Isis additional research support and potential milestone payments (3/19)

Genencor International Inc. (GCOR)

DuPont Pharmaceuticals Inc.

Expanded multiyear research and development collaboration focused on metabolic pathway engineering

ND

Genencor will receive research and development funding, potential milestone payments and royalties on product sales (3/12)

LION Bioscience AG (Germany; LEON)

Intervet International GmbH (the Netherlands)

Extension to their bioinformatics collaboration

ND

The extension includes licenses for the data integration technology SRS and the automated gene and genome annotation system bioSCOUT, in addition to new licenses for genomeSCOUT gene comparison software and SRS everEST (3/6)

Metabasis Therapeutics Inc.*

Sankyo Co. Ltd. (Japan)

Extension to the joint research collaboration to develop oral drugs to treat diabetes mellitus

ND

Sankyo will extend research funding to Metabasis through May 2002 (3/21)

Phase-1 Molecular Toxicology Inc.*

Bayer AG (Germany)

Extension to an existing toxicogenomic collaboration

ND

Phase-1 will supply a package of toxicogenomic products and services to Bayer, including its rat toxicology database TOXbank and MATRIXexpress software (4/5)

Vernalis Group plc (UK; LSE:VER)

Eli Lilly & Co.

Extended license agreement to develop VML 670 as a treatment for sexual dysfunction

ND

The original license, signed in October 1998, was to develop the product to treat delayed emesis in patients receiving cancer chemotherapy (3/20)

II. TERMINATED AGREEMENTS

Biotech Co.* (Symbol)

Pharma Co. (Country)

Change from original agreement

Disclosed Funding (M)

Terms/Details (Date)

Unigene Laboratories Inc. (OTC BB:UGNE)

Pfizer Inc.

Terminated oral calcitonin license agreement

ND

All the rights to oral calcitonin will revert to Unigene, which will acquire all of the technology and data developed by Pfizer in connection with the program (3/26)

NOTES

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market.

ND = Not disclosed, reported and/or available

LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board

No Comments